Adam Koppel

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA.

Newton-Wellesley Hospital Corp. provides health care services. Its services include medical, surgical and diagnostic services. The company was founded in 1881 and is headquartered in Newton, MA.

Museum of Science operates as a museum. The company was founded in 1830 and is headquartered in Boston, MA.

Temple Beth Elohim provides community support services. The non-profit company is based in Wellesley, MA.

Bain Capital Life Sciences LP (Bain Capital Life Sciences) is a private equity subsidiary of Bain Capital Private Equity LP, ultimately held by Bain Capital Holdings LP, founded in 2016. The firm is headquartered in Boston, Massachusetts.

Cardurion Pharmaceuticals LLC is a cardiovascular biotechnology company, which engages in the development of therapeutics for the treatment of heart failure and cardiovascular diseases. The company was founded by Michael E. Mendelsohn in 2017 and is headquartered in Boston, MA.

Cerevel Therapeutics LLC operates as a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system. The company was founded in 2018 and is headquartered in Boston, MA.

BCLS Acquisition Corp. is a blank check company, which engages in seeking a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on August 26, 2020 and is headquartered in Boston, MA.

Aavantibio, Inc. engages in developing gene therapies. The company was founded by Barry Byrne and Manuela Corti and is headquartered in Gainesville, FL.

Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The private company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018.

Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials.